Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit (Details 2)

v3.19.1
Stockholders' Deficit (Details 2) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Equity [Abstract]    
Research and development Options Expense $ 43,174
Total research and development expenses 686,914 55,508
General and administrative Options Issuance Expense 85,976 69,161
Stock issued to consultants 154,854  
Total general and administrative expenses 1,562,352 284,005
Total stock-based compensation expense $ 284,004 $ 69,161